obé

ObeTherapy Biotechnology is a French biotechnology company specializing in the discovery of novel therapeutic targets for obesity and metabolic disorders. Founded in 2000 and headquartered in the Genopole biocluster in Évry, the company pioneered a "lean phenotype" approach, identifying genes and enzymes associated with rare genetic conditions that result in a failure to absorb energy. By targeting these "lean genes," ObeTherapy develops small molecule candidates designed to inhibit the absorption of lipids, proteins, and carbohydrates in the gastrointestinal tract. The company has historically collaborated with partners such as the Zambon Group to advance its research from target identification through preclinical validation.